Tradestie Institutional Equity Comparison Engine · Market Close Nov 16, 2026

UFPT vs ENOV: Which Stock Is the Better Buy Now?

Deterministic 6-pillar institutional evaluation across valuation multiples, TTM & multi-year operating margins, cash generation, options IV skew, and supply-chain moat.

UFPT Wins Head-to-Head Institutional Verdict (3–2 across 6 Pillars · 7–2 Matrix Metrics)

UFPT Overall Winner 6-Pillar Tally: UFPT 3 – 2 ENOV (1 Tie) Matrix Metrics: UFPT 7 – 2 ENOV

As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over Enovis Corporation (ENOV) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas ENOV carries 27.7/100 (SELL) at $27.92 (8.1x Forward P/E, 4.0% operating margin).

  • Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile ENOV trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 66.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

Executive Snapshot Side-by-Side Composite Ratings & Technical Regime

Ask Alpha AI About UFPT vs ENOV
UFPT NASDAQ Head-to-Head Winner
UFP Technologies Inc
Surgical & Medical Instruments & Apparatus
$298.54
-2.14% 1D
Market Cap $2.4B
TTM Revenue $650M
Forward P/E 24.7x
Beta / 30D Vol 1.64β · 77% Vol
Unified Composite Score
42.6 / 100 HOLD
Tech 25.0 Fund 37.0 Flow 50.0 Mom 40.0
Weinstein Technical Phase Distribution · Trim / tighten stop
Price near a flattening SMA50 (slope -1.1%) with fading momentum, RSI 50
RSI-14: 49.8 · SMA20: $298.97 · SMA50: $293.17
ENOV NYSE
Enovis Corporation
Orthopedic, Prosthetic & Surgical Appliances & Supplies
$27.92
+0.87% 1D
Market Cap $1.6B
TTM Revenue $2.31B
Forward P/E 8.1x
Beta / 30D Vol 0.78β · 101% Vol
Unified Composite Score
27.7 / 100 SELL
Tech 50.0 Fund 29.0 Flow 50.0 Mom 46.0
Weinstein Technical Phase Neutral · Hold
Mixed signals - no dominant trend phase, RSI 67
RSI-14: 66.8 · SMA20: $24.08 · SMA50: $20.70

6-Pillar Scorecard Institutional Category Breakdown (UFPT 3 – 2 ENOV)

Columns: Metric · UFPT · ENOV
1. Valuation Multiples ENOV
Forward P/E 24.7x 8.1x
Trailing P/E 31.2x 7.7x
PEG Ratio 3.80x 1.90x
EV / Revenue 3.6x 0.7x
2. Growth & Scale UFPT
Revenue Growth (YoY) +11.6% +1.8%
Earnings Growth (YoY) +25.1% +153.1%
TTM Revenue (USD) $650M $2.31B
Market Cap $2.4B $1.6B
3. Profitability & Quality UFPT
Gross Margin 28.9% 61.3%
Operating Margin 15.4% 4.0%
Net Profit Margin 11.8% -22.9%
Return on Equity (ROE) 17.2% -29.9%
4. Balance Sheet & Cash Flow UFPT
Cash Generation (TTM) $120M EBITDA $387M EBITDA
Cash Flow Margin 18.5% EBITDA Mgn 16.8% EBITDA Mgn
Net Cash / Leverage $62.70 Book/Sh · 17.2% ROE $25.88 Book/Sh · -29.9% ROE
Dividend Yield None (0.00%) None (0.00%)
5. Options & Positioning Tie
Options Structure Phase UNCLASSIFIED UNCLASSIFIED
Current IV / %ile 42.3% (3rd %ile) 65.6% (43rd %ile)
Put/Call OI Skew N/A N/A
OBV Trend / Tech Phase NEUTRAL · Distribution NEUTRAL · Neutral
6. R&D & Supply-Chain Moat ENOV
OpEx & R&D Intensity 13.5% of Rev ($88M) 57.3% of Rev ($1.32B)
90D R&D Disclosures 0 papers 0 papers
Competitive Moat Scale & Operating Efficiency Moat Cyclical / Execution-Driven Positioning
Supply-Chain Role Medical Devices Operator Medical Devices Operator

Core Matrix Head-to-Head Valuation, Margin, Cash Flow & Risk Table

Core Matrix Wins: UFPT (7) vs ENOV (2)
Institutional Metric UFPT ENOV Criterion Row Edge
Market Capitalization
Scale
$2.4B $1.6B Larger Scale UFPT
Trailing P/E Ratio
Valuation
31.2x 7.7x Lower Multiple ENOV
Forward P/E Ratio
Valuation
24.7x 8.1x Lower Multiple ENOV
Revenue Growth (YoY)
Growth
+11.6% +1.8% Higher Growth UFPT
Operating Margin (TTM)
Profitability
15.4% 4.0% Higher Margin UFPT
Net Profit Margin
Profitability
11.8% -22.9% Higher Margin UFPT
Return on Equity (ROE)
Capital Efficiency
17.2% -29.9% Higher ROE UFPT
52-Week Range Position
Momentum
74% ($174–$342) 74% ($17–$32) Stronger Trend Tie
Beta / 30D Volatility
Risk Regime
1.64β · 77% Vol 0.78β · 101% Vol Lower Realized Risk UFPT
Unified Institutional Score
Composite Signal
42.6 / 100 (HOLD) 27.7 / 100 (SELL) Higher Composite UFPT
Trailing 12M Revenue (USD)
Operating Scale
$650M $2.31B FX-Normalized USD Scale
Gross Profit Margin (TTM)
Unit Pricing Power
28.9% 61.3% Higher Margin Quality
PEG Ratio & EV / Revenue
Growth-Adjusted Valuation
3.80x PEG · 3.6x EV/Rev 1.90x PEG · 0.7x EV/Rev Lower Multiple Valuation
Cash Flow & Balance Sheet
Capital Self-Funding
$120M EBITDA ($62.70 Book/Sh · 17.2% ROE) $387M EBITDA ($25.88 Book/Sh · -29.9% ROE) Higher Cash / Net Cash Solvency

Momentum Normalized Relative Price Performance (1M · 3M · 6M · 1Y)

1M Horizon ENOV +40.16 pp
UFPT: +2.36% · ENOV: +42.52%
3M Horizon ENOV +13.81 pp
UFPT: -4.92% · ENOV: +8.89%
6M Horizon UFPT +26.87 pp
UFPT: +37.44% · ENOV: +10.57%
1Y Horizon UFPT +36.98 pp
UFPT: +27.42% · ENOV: -9.56%

Financial Trajectory Operating Profitability Benchmark (Trailing 12-Month)

Split-Invariant USD Revenue & Operating Margin (%)

Standardized multi-year USD domestic revenue schedules are unavailable for foreign-domiciled ADR filing schedules on UFPT vs ENOV. Trailing 12-month operating profitability (UFPT 15.4% vs ENOV 4.0%) and valuation multiples (UFPT 24.7x vs ENOV 8.1x Forward P/E) are benchmarked directly in Pillar 4 below.

UFPT ADR TTM Benchmark FX-Normalized USD
TTM Revenue$650M
Gross Margin28.9%
Op. Margin15.4%
ROE / Fwd P/E17.2% · 24.7x
ENOV ADR TTM Benchmark FX-Normalized USD
TTM Revenue$2.31B
Gross Margin61.3%
Op. Margin4.0%
ROE / Fwd P/E-29.9% · 8.1x

Options Positioning Implied Volatility, Put/Call Skew & Dealer Gamma Corridor

Live Options Phase Tracker
UFPT UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 42.3%
IV Percentile 3rd %ile
Put/Call OI Skew N/A
IV Regime Compressed (<25th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact UFPT Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →
ENOV UNCLASSIFIED
0d in phase · OBV NEUTRAL
Current IV 65.6%
IV Percentile 43rd %ile
Put/Call OI Skew N/A
IV Regime Balanced (25th–60th %ile)
Put Wall Floor Pro Only
Call Wall Magnet Pro Only
Net Delta Signal NEUTRAL
OBV Flow NEUTRAL
Exact ENOV Put/Call Gamma Wall strikes & dealer pinning corridor require Tradestie Pro. Unlock 14-Day Free Trial →

Moat & R&D Supply-Chain Positioning, Bottleneck Moat & R&D Velocity

Corporate R&D & Foundry Leaderboard
UFPT Moat Profile Scale & Operating Efficiency Moat
Medical Devices Operator
Competes within the Medical Devices value chain with $2.4B market capitalization and 15.4% operating margin.
OpEx & R&D Reinvestment 13.5% of Rev ($88M)
90D Engineering Disclosures 0 Published
ENOV Moat Profile Cyclical / Execution-Driven Positioning
Medical Devices Operator
Competes within the Medical Devices value chain with $1.6B market capitalization and 4.0% operating margin.
OpEx & R&D Reinvestment 57.3% of Rev ($1.32B)
90D Engineering Disclosures 0 Published

Investor FAQ UFPT vs ENOV Key Questions & Quantitative Answers

As of Nov 16, 2026, UFP Technologies Inc (UFPT) is the stronger overall head-to-head candidate over Enovis Corporation (ENOV) in the Tradestie Institutional Equity Comparison Engine, winning 7–2 core matrix metrics and 3–2 across our 6-pillar institutional scorecard (led by Growth & Scale, Profitability & Quality, Balance Sheet & Cash Flow). UFPT carries a Unified Composite Score of 42.6/100 (HOLD) at $298.54 (24.7x Forward P/E, 15.4% operating margin), whereas ENOV carries 27.7/100 (SELL) at $27.92 (8.1x Forward P/E, 4.0% operating margin). Technical & Structure Timing Caution: UFPT is currently in a Weinstein Distribution regime near a flattening 50-day moving average (RSI 49.8); meanwhile ENOV trades in a Neutral technical trend (UNCLASSIFIED options phase, RSI 66.8). Short-term Markdown, Distribution, or Breakdown phases signal active supply overhead rather than bullish technical support — disciplined entries typically wait for price to reclaim the 20/50-day moving average.

UFPT leads the Growth & Scale pillar: UFPT posts +11.6% YoY revenue growth and +25.1% YoY earnings growth on $650M TTM revenue (28.9% gross margin, 15.4% operating margin), compared with ENOV at +1.8% YoY revenue growth and +153.1% YoY earnings growth on $2.31B TTM revenue (61.3% gross margin, 4.0% operating margin). On trailing 12-month operating scale, UFPT generates $650M in USD-normalized revenue versus $2.31B for ENOV. In operating R&D and SG&A reinvestment, UFPT deploys 13.5% of Rev ($88M) (0 90-day corporate R&D disclosures) versus 57.3% of Rev ($1.32B) (0 disclosures) for ENOV.

ENOV screens cheaper on headline valuation multiples. UFPT trades at 24.7x Forward P/E, 31.2x Trailing P/E, 3.80x PEG, and 3.6x EV/Revenue (18.5% EBITDA margin), whereas ENOV trades at 8.1x Forward P/E, 7.7x Trailing P/E, 1.90x PEG, and 0.7x EV/Revenue (16.8% EBITDA margin). Multiples above 150x or negative earnings denominators are marked N/M to avoid distorted accounting comparisons; weigh lower Forward P/E and PEG against UFPT (17.2% ROE) versus ENOV (-29.9% ROE) capital efficiency.

In options market volatility and institutional positioning, UFPT carries 42.3% implied volatility (3rd %ile, Compressed (<25th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (1.64β · 77% Vol realized risk). By comparison, ENOV carries 65.6% implied volatility (43rd %ile, Balanced (25th–60th %ile)), unclassified Put/Call open interest, NEUTRAL on-balance volume, and sits in an UNCLASSIFIED options structure phase (0.78β · 101% Vol realized risk).

Cross-Compare 1-Click Peer Rivalries & Single-Stock Research

Launch Custom Ticker Comparison →

Powered by Tradestie Institutional Equity Comparison Engine & standardized corporate financial telemetry. Market close as of Nov 16, 2026. For educational research only; not investment advice.